VSF-173 Study in Healthy Adult Volunteers for Treatment of Induced Excessive Sleepiness

Vanda Pharmaceuticals

Status and phase: Completed; Phase 2

Conditions: Excessive Somnolence

Treatments: Drug: VSF-173

Study type: Interventional

Funder types: Industry

Identifiers

NCT00467441

VP-VSF-173-2001

Details and patient eligibility

About

The purpose of this study is to determine the safety and efficacy of VSF-173 compared to placebo in treatment of induced excessive sleepiness.

Enrollment: 60 estimated patients

Sex: All

Ages: 18 to 40 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Healthy subjects with no medical, psychiatric, or current sleep disorders
• Subject must sign a written consent form

Exclusion criteria

• Evidence of excessive daytime sleepiness
• History of sleep disorders
• Psychiatric or neurological disorders

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind